Articles By Anuja Singh
Can Hippocratic AI’s Acquisition of Grove AI Trigger the Shift from Fragmented Pilots to…
Executive SummaryAt the 2026 JPM Healthcare Conference in San Francisco, Hippocratic AI announced the acquisition of Grove AI,…
ByInnovent and Eli Lilly Expand Strategic Alliance to Advance Immunology and Oncology Innovation
Shanghai, China – February, 2026 – Innovent Biologics Inc today announced a new strategic collaboration with Eli Lilly…
Eli Lilly to Acquire Orna Therapeutics in Deal Valued at Up to $2.4 Billion…
Indianapolis, IN – February 9, 2026 – Eli Lilly and Company today announced it has entered into a…
AstraZeneca Reports 2025 Performance with Strong Brand Momentum Across Core Therapeutic Areas
AstraZeneca today announced its full-year 2025 results, reflecting continued growth across oncology, cardiovascular-renal-metabolism (CVRM), respiratory & immunology, and…
GSK Reports Full-Year 2025 Results with Strategic Portfolio Focus
GSK today reported its full-year performance for 2025 and outlined its strategic approach to long-term growth across vaccines,…
Roche Reports Full-Year 2025 Results and Provides Strategic Portfolio Insights
Roche today announced its full-year 2025 performance and outlined its strategic positioning across key therapeutic areas. Roche maintained…
Can Hippocratic AI’s Acquisition of Grove AI Trigger the Shift from Fragmented Pilots to…
Executive SummaryAt the 2026 JPM Healthcare Conference in San Francisco, Hippocratic AI announced the acquisition of Grove AI,…
Innovent and Eli Lilly Expand Strategic Alliance to Advance Immunology and Oncology Innovation
Shanghai, China – February, 2026 – Innovent Biologics Inc today announced a new strategic collaboration with Eli Lilly…
Eli Lilly to Acquire Orna Therapeutics in Deal Valued at Up to $2.4 Billion…
Indianapolis, IN – February 9, 2026 – Eli Lilly and Company today announced it has entered into a…
AstraZeneca Reports 2025 Performance with Strong Brand Momentum Across Core Therapeutic Areas
AstraZeneca today announced its full-year 2025 results, reflecting continued growth across oncology, cardiovascular-renal-metabolism (CVRM), respiratory & immunology, and…
GSK Reports Full-Year 2025 Results with Strategic Portfolio Focus
GSK today reported its full-year performance for 2025 and outlined its strategic approach to long-term growth across vaccines,…
Roche Reports Full-Year 2025 Results and Provides Strategic Portfolio Insights
Roche today announced its full-year 2025 performance and outlined its strategic positioning across key therapeutic areas. Roche maintained…